CD274 and non-small cell lung carcinoma: Durvalumab, a programmed cell death-ligand 1 (PD-L1) inhibitor, as consolidation therapy after CCRT, is standard care for patients with unresectable locally advanced NSCLC (LA-NSCLC), exhibiting a survival benefit of 5-year overall survival (OS) rate of 42.9% [9].